RAPT - RAPT Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

RAPT Therapeutics, Inc.

561 Eccles Avenue
South San Francisco, CA 94080
United States
650-489-9000
http://www.flxbio.com

SectorIndustrial Goods
IndustryWaste Management
Full Time Employees64

Key Executives

NameTitlePayExercisedYear Born
Dr. Brian Russell WongCEO, Pres & DirectorN/AN/A1971
Mr. Eric J. Hall C.F.A., CFAInterim CFO & Sec.N/AN/A1954
Steve Young Ph.D.VP of TechnologyN/AN/AN/A
Dr. Dirk G. Brockstedt Ph.D.Chief Scientific OfficerN/AN/A1969
Ms. Erin CampanyVP of HRN/AN/A1967
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

RAPT Therapeutics, Inc., a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases. Its lead oncology drug candidate is FLX475 for the treatment of a range of tumors; and RPT193, a CCR4 antagonist for allergic inflammatory disease. The company is also pursuing a range of targets, including general control nonderepressible and hematopoietic progenitor kinase for the treatment of cancer. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

Corporate Governance

RAPT Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.